Srensen says that Bavarian Nordic was contracted to develop a safer vaccine for the US in the early 2000s. Jynneos have been produced and stored by the company for a long time.
Srensen doesn't think there's a shortage of the vaccine. He said that the company has fulfilled every request it has received since the outbreak began.
Srensen says that they haven't seen any requests that are over capacity. There is a limitation but we think it's a ghost.
Srensen said that the ability to deliver these doses has been down to luck. He says that when the outbreak came, they had 2 million doses of their own vaccine in addition to the US vaccine. That was the first thing we began to sell.
The company has increased production and there are very few left.
It's hopefully. The US Strategic National Stockpile, an emergency store of medicines and medical supplies, contains millions of doses of ACAM2000 and Jynneos.
There are believed to be more countries with vaccine for the disease. Heymann doesn't think it's known which countries have the most vaccine and which have the least.
The WHO wants countries that have the vaccine to give it to those that don't. The vaccine for the monkeypox is not available in the African countries where the virus is endemic.
Heymann thinks we all need to be concerned about access to vaccines. He points out that the vaccines were developed to be used in the first place. He says that they were sold to countries for use in bioterrorists.
Without the drive to create vaccine stockpiles, we wouldn’t have Jynneos. “It’s a real Catch-22, isn’t it,” says Hermann. “It’s a complicated issue. We need [incentives and financial support to make] these vaccines, but at the same time we need them to be shared as widely as possible.”
All Rights Reserved © 2024
